参考文献/References:
[1] Di Bartolo P,Eckel RH,Strollo F,et al.Hundred-year experience with insulin and lipohypertrophy:an unresolved issue[J].Diabetes Res Clin Pract,2021,178:108924.DOI:10.1016/j.diabres.2021.108924.
[2] Song Z,Guo X,Ji L,et al.Insulin injection technique in China compared with the rest of the world[J].Diabetes Ther,2018,9(6):2357-2368.DOI:10.1007/s13300-018-0525-y.
[3] Ji L,Sun Z,Li Q,et al.Lipohypertrophy in China:prevalence,risk factors,insulin consumption,and clinical impact[J].Diabetes Technol Ther,2017,19(1):61-67.DOI:10.1089/dia.2016.0334.
[4] Deng N,Zhang X,Zhao F,et al.Prevalence of lipohypertrophy in insulin-treated diabetes patients:a systematic review and meta-analysis[J].J Diabetes Investig,2017,9(3):536-543.DOI:10.1111/jdi.12742.
[5] Li FF,Fu SM,Liu ZP,et al.Injection sites lipohypertrophy among 736 patients with type 2 diabetes of different-grade hospitals[J].Int J Clin Exp Med,2016,9(7):13178-13183.
[6] Sürücü HA,OKur Arslan H.Lipohypertrophy in individuals with type 2 diabetes:prevalence and risk factors[J].J Caring Sci,2018,7(2):67-74.DOI:10.15171/jcs.2018.011.
[7] Wang K,Zhang S,Liu C,et al.A meta-analysis and meta-regression on the prevalence of lipohypertrophy in diabetic patients on insulin therapy[J].Therapie,2021,S0040-5957(21)00098-6.DOI:10.1016/j.therap.2021.04.002.
[8] Gentile S,Guarino G,Della Corte T,et al.Lipohypertrophy in elderly insulin-treated patients with type 2 diabetes[J].Diabetes Ther,2021,12(1):107-119.DOI:10.1007/s13300-020-00954-3.
[9] Kordonouri O,Lauterborn R,Deiss D.Lipohypertrophy in young patients with type 1 diabetes[J].Diabetes Care,2002,25(3):634.DOI:10.2337/diacare.25.3.634.
[10] Al Hayek AA,Robert AA,Braham RB,et al.Frequency of lipohypertrophy and associated risk factors in young patients with type 1 diabetes:a cross-sectional study[J].Diabetes Ther,2016,7(2):259-267.DOI:10.1007/s13300-016-0161-3.
[11] Gupta SS,Gupta KS,Gathe SS,et al.Clinical implications of lipohypertrophy among people with type 1 diabetes in India[J].Diabetes Technol Ther,2018,20(7):483-491.DOI:10.1089/dia.2018.0074.
[12] 吴伟英,叶凯云,梁干雄,等.1型糖尿病患者脂肪增生的相关因素分析及预防护理措施[J].中国实用护理杂志,2016,32(9):677-678.DOI:10.3760/cma.j.issn.1672-7088.2016.09.009.
[13] Luo D,Shi Y,Zhu M,et al.Subclinical lipohypertrophy--Easily ignored complications of insulin therapy[J].J Diabetes Complications,2021,35(3):107806.DOI:10.1016/j.jdiacomp.2020.107806.
[14] Tandon N,Kalra S,Balhara YP,et al.Forum for injection technique(FIT),India:the Indian recommendations 2.0,for best practice in insulin injection technique,2015[J].Indian J Endocrinol Metab,2015,19(3):317-331.DOI:10.4103/2230-8210.152762.
[15] Blanco M,Hernández MT,Strauss KW,et al.Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes[J].Diabetes Metab,2013,39(5):445-453.DOI:10.1016/j.diabet.2013.05.006.
[16] Al Ajlouni M,Abujbara M,Batieha A,et al.Prevalence of lipohypertrophy and associated risk factors in insulin-treated patients with type 2 diabetes mellitus[J].Int J Endocrinol Metab,2015,13(2):e20776.DOI:10.5812/ijem.20776.
[17] Vardar B,Kizilci S.Incidence of lipohypertrophy in diabetic patients and a study of influencing factors[J].Diabetes Res Clin Pract,2007,77(2):231-236.DOI:10.1016/j.diabres.2006.12.023.
[18] Ji L,Gao L,Chen L,et al.Insulin delivery with a needle-free insulin injector versus a conventional insulin pen in Chinese patients with type 2 diabetes mellitus:a 16-week,multicenter,randomized clinical trial(the FREE study)[J].EClinicalMedicine,2020,23:100368.DOI:10.1016/j.eclinm.2020.100368.
[19] Barola A,Tiwari P,Bhansali A,et al.Insulin-related lipohypertrophy:lipogenic action or tissue trauma?[J].Front Endocrinol(Lausanne),2018,9:638.DOI:10.3389/fendo.2018.00638.
[20] 纪立农,孙子林,李启富,等.中国四城市糖尿病患者胰岛素注射相关皮下脂肪增生的横断面研究[J].中国糖尿病杂志,2019,27(10):721-727.DOI:10.3969/j.issn.1006-6187.2019.10.001.
[21] Fujikura J,Fujimoto M,Yasue S,et al.Insulin-induced lipohypertrophy:report of a case with histopathology[J].Endocr J,2005,52(5):623-628.DOI:10.1507/endocrj.52.623.
[22] Hauner H,Stockamp B,Haastert B.Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors[J].Exp Clin Endocrinol Diabetes,1996,104(2):106-110.DOI:10.1055/s-0029-1211431.
[23] Baruah MP,Kalra S,Bose S,et al.An audit of insulin usage and insulin injection practices in a large Indian cohort[J].Indian J Endocrinol Metab,2017,21(3):443-452.DOI:10.4103/ijem.IJEM_548_16.
[24] Hajheydari Z,Kashi Z,Akha O,et al.Frequency of lipodystrophy induced by recombinant human insulin[J].Eur Rev Med Pharmacol Sci,2011,15(10):1196-1201.
[25] Petersen MC,Shulman GI.Mechanisms of insulin action and insulin resistance[J].Physiol Rev,2018,98(4):2133-2223.DOI:10.1152/physrev.00063.2017.
[26] Ng CM,Chui OL,Tiu SC.‘Cleft sign’ of severe lipohypertrophy[J].Hong Kong Med J,2015,21(5):475.e3-4.DOI:10.12809/hkmj154528.
[27] Teft G.Lipohypertrophy:patient awareness and implications for practice[J].Journal of Diabetes Nursing,2002,6:20-23.
[28] Frid AH,Hirsch LJ,Menchior AR,et al.Worldwide injection technique questionnaire study:injecting complications and the role of the professional[J].Mayo Clin Proc,2016,91(9):1224-1230.DOI:10.1016/j.mayocp.2016.06.012.
[29] Famulla S,H?elmann U,Fischer A,et al.Insulin injection into lipohypertrophic tissue:blunted and more variable insulin absorption and action and impaired postprandial glucose control[J].Diabetes Care,2016,39(9):1486-1492.DOI:10.2337/dc16-0610.
[30] Barola A,Tiwari P,Bhansali A.Insulin-mediated lipohypertrophy:an uncommon cause of diabetic ketoacidosis[J].BMJ Case Rep,2017,2017:bcr2017220387.DOI:10.1136/bcr-2017-220387.
[31] Al-Hayek AA,Robert AA,Braham RB,et al.Frequency and associated risk factors of recurrent diabetic ketoacidosis among Saudi adolescents with type 1 diabetes mellitus[J].Saudi Med J,2015,36(2):216-220.DOI:10.15537/smj.2015.2.10560.
[32] Gradel AKJ,Porsgaard T,Lykkesfeldt J,et al.Factors affecting the absorption of subcutaneously administered insulin:effect on variability[J].J Diabetes Res,2018,2018:1205121.DOI:10.1155/2018/1205121.
[33] Gentile S,Satta E,Strollo F,et al.Insulin-induced skin lipohypertrophies:a neglected cause of hypoglycemia in dialysed individuals with diabetes[J].Diabetes Metab Syndr,2021,15(4):102145.DOI:10.1016/j.dsx.2021.05.018.
[34] Gentile S,Strollo F,Corte TD,et al.Skin complications of insulin injections:a case presentation and a possible explanation of hypoglycaemia[J].Diabetes Res Clin Pract,2018,138:284-287.DOI:10.1016/j.diabres.2018.02.005.
[35] Ji L,Chandran A,Inocencio TJ,et al.The association between insurance coverage for insulin pen needles and healthcare resource utilization among insulin-dependent patients with diabetes in China[J].BMC Health Serv Res,2018,18(1):300.DOI:10.1186/s12913-018-3095-9.
[36] 纪立农,郭晓蕙,黄金,等.中国糖尿病药物注射技术指南(2016年版)[J].中华糖尿病杂志,2017,9(2):79-105.DOI:10.3760/cma.j.issn.1674-5809.2017.02.005.
[37] Abu Ghazaleh H,Hashem R,Forbes A,et al.A systematic review of ultrasound-detected lipohypertrophy in insulin-exposed people with diabetes[J].Diabetes Ther,2018,9(5):1741-1756.DOI:10.1007/s13300-018-0472-7.
[38] Bertuzzi F,Meneghini E,Bruschi E,et al.Ultrasound characterization of insulin induced lipohypertrophy in type 1 diabetes mellitus[J].J Endocrinol Invest,2017,40(10):1107-1113.DOI:10.1007/s40618-017-0675-1.
[39] Nilsson MR.Insulin amyloid at injection sites of patients with diabetes[J].Amyloid,2016,23(3):139-147.DOI:10.1080/13506129.2016.1179183.
[40] Gentile S,Guarino G,Giancaterini A,et al.A suitable palpation technique allows to identify skin lipohypertrophic lesions in insulin-treated people with diabetes[J].Springerplus,2016,5:563.DOI:10.1186/s40064-016-1978-y.
[41] Xu XH,Carvalho V,Wang XH,et al.Lipohypertrophy:prevalence,clinical consequence,and pathogenesis[J].Chin Med J(Engl),2020,134(1):47-49.DOI:10.1097/CM9.0000000000000970.
[42] Richardson T,Kerr D.Skin-related complications of insulin therapy:epidemiology and emerging management strategies[J].Am J Clin Dermatol,2003,4(10):661-667.DOI:10.2165/00128071-200304100-00001.
[43] Kapeluto JE,Paty BW,Chang SD,et al.Ultrasound detection of insulin-induced lipohypertrophy in type 1 and type 2 diabetes[J].Diabet Med,2018,35(10):1383-1390.DOI:10.1111/dme.13764.
[44] Kapeluto JE,Paty BW,Chang SD,et al.Meneilly Criteria for the detection of insulin-induced lipohypertrophy using ultrasonography[J].Can J Diabetes,2015,39(9):534.DOI:10.1016/j.jcjd.2015.09.032
[45] Arora S,Agrawal NK,Shanthaiah DM,et al.Early detection of cutaneous complications of insulin therapy in type 1 and type 2 diabetes mellitus[J].Prim Care Diabetes,2021,15(5):859-864.DOI:10.1016/j.pcd.2021.06.004.
[46] Wang W,Huang R,Chen Y,et al.Values of ultrasound for diagnosis and management of insulin-induced lipohypertrophy:A prospective cohort study in China[J].Medicine(Baltimore),2021,100(29):e26743.DOI:10.1097/MD.0000000000026743.
[47] 朱敏, 王洪, 沈敏, 等. 高频超声在胰岛素注射皮下脂肪增生临床筛查中的应用[J].中华糖尿病杂志,2021,13(8):809-813.DOI:10.3760/cma.j.cn115791-20201209-00706.
[48] Kalra S,Kumar A,Gupta Y.Prevention of lipohypertrophy[J].J Pak Med Assoc,2016,66(7):910-911.
[49] Gentile S,Guarino G,Della Corte T,et al.The durability of an intensive,structured education-based rehabilitation protocol for best insulin injection practice:the ISTERP-2 study[J].Diabetes Ther,2021,12(9):2557-2569.DOI:10.1007/s13300-021-01108-9.
[50] Campinos C,Le Floch JP,Petit C,et al.An effective intervention for diabetic lipohypertrophy:results of a randomized,controlled,prospective multicenter study in France[J].Diabetes Technol Ther,2017,19(11):623-632.DOI:10.1089/dia.2017.0165.
[51] Smith M,Clapham L,Strauss K.UK lipohypertrophy interventional study[J].Diabetes Res Clin Pract,2017,126:248-253.DOI:10.1016/j.diabres.2017.01.020.
[52] Gentile S,Guarino G,Della Corte T,et al.Role of structured education in reducing lypodistrophy and its metabolic complications in insulin-treated people with type 2 diabetes:a randomized multicenter case-control study[J].Diabetes Ther,2021,12(5):1379-1398.DOI:10.1007/s13300-021-01006-0.
[53] Bochanen N,Decochez K,Heleu E,et al.Lipohypertrophy Monitoring Study(LIMO):Effect of single use of 4 mm pen needles combined with education on injection site rotation on glycaemic control:confirmation of an unpleasant truth[J].Diabet Med,2021:e14672.DOI:10.1111/dme.14672.
[54] Wallymahmed ME,Littler P,Clegg C,et al.Nodules of fibrocollagenous scar tissue induced by subcutaneous insulin injections:a cause of poor diabetic control[J].Postgrad Med J,2004,80(950):732-733.DOI:10.1136/pgmj.2004.019547.
[55] Brun A,Comparin JP,Voulliaume D,et al.[Insulin-induced lipohypertrophy treated by liposuction][J].Ann Chir Plast Esthet,2007,52(3):218-221.DOI:10.1016/j.anplas.2007.02.003.
[56] Singha A,Bhattarcharjee R,Ghosh S,et al.Concurrence of lipoatrophy and lipohypertrophy in children with type 1 diabetes using recombinant human insulin:two case reports[J].Clin Diabetes,2016,34(1):51-53.DOI:10.2337/diaclin.34.1.51.